B E Shaw

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations
    B E Shaw
    Department of Haematology, Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 45:832-8. 2010
  2. doi Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles
    B E Shaw
    Research Department, Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Leukemia 24:58-65. 2010
  3. doi Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
  4. doi Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation
    B E Shaw
    1 Anthony Nolan Research Institute, Royal Free Hospital, UCL Cancer Centre, London, UK 2 Royal Marsden NHS Foundation Trust, London, UK
    Bone Marrow Transplant 48:1506-9. 2013
  5. doi Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD
    F L Dignan
    1 St John s Institute of Dermatology, St Thomas Hospital, London, UK 2 Section of Haemato oncology, The Royal Marsden Hospital, Sutton, UK 3 University College London, Cancer Institute, London, UK
    Bone Marrow Transplant 49:704-8. 2014
  6. doi The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, UK
    Int J Immunogenet 35:367-74. 2008
  7. doi Related hematopoietic cell donor care: is there a role for unrelated donor registries?
    C Anthias
    Anthony Nolan Research Institute, UCL Cancer Centre, London, UK
    Bone Marrow Transplant 50:637-41. 2015
  8. doi Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study
    P G Medd
    Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK
    Bone Marrow Transplant 48:982-7. 2013
  9. ncbi Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005
    R F Duarte
    The Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 37:901-8. 2006
  10. doi Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation
    B E Shaw
    1 Anthony Nolan Research Institute, Royal Free Hospital, London, UK 2 UCL Cancer Institute, Royal Free Campus, London, UK 3 Section of Haemato Oncology, Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 50:237-43. 2015

Detail Information

Publications23

  1. doi Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations
    B E Shaw
    Department of Haematology, Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 45:832-8. 2010
    ..One of the principal goals leading to the formation of the World Marrow Donor Association (WMDA) was to establish internationally acceptable standards for all aspects of unrelated donor care...
  2. doi Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles
    B E Shaw
    Research Department, Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Leukemia 24:58-65. 2010
    ..Conversely, our results suggest that in patients receiving an HLA-mismatched graft, the outcome is significantly better if they are also mismatched for DPB1. We recommend validation of these results in independent datasets...
  3. doi Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
    ..014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant...
  4. doi Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation
    B E Shaw
    1 Anthony Nolan Research Institute, Royal Free Hospital, UCL Cancer Centre, London, UK 2 Royal Marsden NHS Foundation Trust, London, UK
    Bone Marrow Transplant 48:1506-9. 2013
    ..The system has a robust governance structure, formal feedback to the WMDA membership and transparent information flows to other agencies, specialist physicians and transplant programs and the general public. ..
  5. doi Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD
    F L Dignan
    1 St John s Institute of Dermatology, St Thomas Hospital, London, UK 2 Section of Haemato oncology, The Royal Marsden Hospital, Sutton, UK 3 University College London, Cancer Institute, London, UK
    Bone Marrow Transplant 49:704-8. 2014
    ..012 and 3.4 compared with 6.9, P=0.009, respectively). This study confirms that ECP can lead to objective clinical responses and, in addition, may lead to an improvement in QoL in cGVHD. ..
  6. doi The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, UK
    Int J Immunogenet 35:367-74. 2008
    ..The findings of this study have made it possible to offer advice concerning the choice of the most appropriate unrelated donor to select in order to achieve the best patient outcomes...
  7. doi Related hematopoietic cell donor care: is there a role for unrelated donor registries?
    C Anthias
    Anthony Nolan Research Institute, UCL Cancer Centre, London, UK
    Bone Marrow Transplant 50:637-41. 2015
    ....
  8. doi Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study
    P G Medd
    Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK
    Bone Marrow Transplant 48:982-7. 2013
    ..035 and HR = 0.52, P = 0.025, respectively). Long-term ALL-free survival is achievable following fludarabine-based RIC allo-SCT. The association between GVHD and decreased RI suggests the presence of a GVL effect...
  9. ncbi Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005
    R F Duarte
    The Anthony Nolan Trust, Royal Free Hospital, London, UK
    Bone Marrow Transplant 37:901-8. 2006
    ....
  10. doi Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation
    B E Shaw
    1 Anthony Nolan Research Institute, Royal Free Hospital, London, UK 2 UCL Cancer Institute, Royal Free Campus, London, UK 3 Section of Haemato Oncology, Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 50:237-43. 2015
    ..These data imply an unrecognized role for the CASP8 promoter polymorphism on survival following unrelated SCT particularly in the context of T-cell depletion with Alemtuzumab. ..
  11. doi A novel HLA-A allele, A*74:23, identified in an individual from Costa Rica
    E Arrieta-Bolaños
    Anthony Nolan Research Institute, Royal Free Hospital, London, UK Royal Free Campus, Cancer Institute, University College London, London, UK Centro de Investigaciones en Hematología y Trastornos Afines CIHATA, Universidad de Costa Rica, San Jose, Costa Rica
    Tissue Antigens 84:583-4. 2014
    ..The new HLA-A*74:23 allele differs from the closest allele A*74:01 by a nucleotide change in exon 3 at codon 97. ..
  12. doi Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee
    R N Lown
    1 Anthony Nolan Research Institute, UCL Cancer Institute, London, UK 2 Royal Marsden NHS Foundation Trust, London, UK
    Bone Marrow Transplant 49:880-6. 2014
    ..Guidance from the WMDA is intended to complement, not supersede, guidance from national competent authorities and international regulatory bodies. ..
  13. doi Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage
    R N Lown
    1 Anthony Nolan Research Institute, Royal Free Hospital, London, UK 2 UCL Cancer Institute, University College London, London, UK
    Bone Marrow Transplant 49:525-31. 2014
    ..99, 2.52, 3.4 and 5.53, respectively, for 1, 2, 3 and 4 risk factors, P<0.001). Donor registries must develop evidence-driven strategies to recruit and retain the most reliable donors. ..
  14. doi The impact of improved JACIE standards on the care of related BM and PBSC donors
    C Anthias
    1 Anthony Nolan Research Institute, London, UK 2 UCL Cancer Institute, University College London, London, UK
    Bone Marrow Transplant 50:244-7. 2015
    ....
  15. doi Novel alleles of the transforming growth factor β-1 regulatory region and exon 1
    E Arrieta-Bolaños
    Anthony Nolan Research Institute, Royal Free Hospital, London, UK Cancer Institute, University College London, Royal Free Campus, London, UK Centro de Investigaciones en Hematología y Trastornos Afines CIHATA, Universidad de Costa Rica, San Jose, Costa Rica
    Tissue Antigens 85:484-91. 2015
    ....
  16. doi Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision
    R N Lown
    Anthony Nolan, London, UK
    Bone Marrow Transplant 48:210-9. 2013
    ....
  17. doi Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD
    F L Dignan
    St John s Institute of Dermatology, St Thomas Hospital, London, UK
    Bone Marrow Transplant 47:824-30. 2012
    ..OS at 3 years from the start of ECP was 69%. This study reports the largest series of patients receiving bimonthly ECP treatment for cGVHD, and confirms that ECP allows successful reduction of immunosuppression...
  18. doi Transforming growth factor-β1 polymorphisms and the outcome of hematopoietic stem cell transplantation
    E Arrieta-Bolaños
    The Anthony Nolan Research Institute, Royal Free and University College Medical School, Pond Street, Hampstead, London, UK
    Int J Immunogenet 39:192-202. 2012
    ..The present review will focus on the current knowledge surrounding the effect of polymorphisms within TGFB1 on the outcome of HSCT...
  19. doi A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies
    B E Shaw
    1 Anthony Nolan Research Institute, UCL Cancer Institute, London, UK 2 Department of Haemato Oncology, Royal Marsden Hospital, Sutton, UK
    Bone Marrow Transplant 50:334-40. 2015
    ..Herein we review the evidence on which this statement is based. ..
  20. doi A review of the haematopoietic stem cell donation experience: is there room for improvement?
    A Billen
    1 UCL Cancer Institute, London, UK 2 Anthony Nolan, London, UK
    Bone Marrow Transplant 49:729-36. 2014
    ..Owing to the relative rarity of donation in each country, a global effort to collect donor outcome data is needed. ..
  21. ncbi Clinical importance of HLA-DPB1 in haematopoietic cell transplantation
    B E Shaw
    Department of Haematology, Nottingham City Hospital, Nottingham, UK
    Tissue Antigens 69:36-41. 2007
    ..33; P-value = <0.0001], while protecting against disease relapse (HR: 0.82, P-value = 0.01). These data support an immunogenic role for HLA-DPB1 in HCT and the need for pretransplant tissue typing at this locus...
  22. ncbi Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK
    Tissue Antigens 63:401-11. 2004
    ..Our results suggest a functional effect of TNFA polymorphisms on myeloid engraftment in unrelated HSCT...
  23. ncbi The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation
    B E Shaw
    Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Bone Marrow Transplant 31:1001-8. 2003
    ..This study provides further evidence for an immunogenic role of HLA-DPB1 in HSC transplants...